Achilles Therapeutics Income Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Other Revenue	18.51	19.72	77.91	40.39	9.85
Revenue	18.51	19.72	77.91	40.39	9.85
Revenue Growth (YoY)	-6.12%	-74.69%	92.89%	310.17%	-
Gross Profit	18.51	19.72	77.91	40.39	9.85
Selling, General & Admin	5.47	5.64	5.71	4.14	2.76
Other Operating Expenses	1.56	1.48	2.41	1.44	0.83
Operating Expenses	7.04	7.12	8.12	5.58	3.59
Operating Income	11.48	12.6	69.79	34.81	6.26
Interest & Investment Income	0.3	0.13	0.05	0.01	0.39
Currency Exchange Gain (Loss)	-	-0.03	-0	-0.03	0.03
Pretax Income	11.78	12.7	69.84	34.79	6.68
Net Income	11.78	12.7	69.84	34.79	6.68
Net Income to Common	11.78	12.7	69.84	34.79	6.68
Net Income Growth	-7.25%	-81.82%	100.74%	420.98%	-
Shares Outstanding (Basic)	562	565	565	424	303
Shares Outstanding (Diluted)	562	565	565	424	303
Shares Change (YoY)	-0.43%	-	33.21%	39.91%	-
EPS (Basic)	0.02	0.02	0.12	0.08	0.02
EPS (Diluted)	0.02	0.02	0.12	0.08	0.02
EPS Growth	-6.84%	-81.82%	50.70%	272.38%	-
Dividend Per Share	0.060	0.058	0.052	0.050	0.025
Dividend Growth	3.97%	10.50%	4.80%	96.54%	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	62.00%	63.90%	89.57%	86.19%	63.54%
Profit Margin	63.62%	64.39%	89.64%	86.13%	67.81%
EBIT	11.48	12.6	69.79	34.81	6.26
EBIT Margin	62.00%	63.90%	89.57%	86.19%	63.54%
Revenue as Reported	18.51	19.72	77.91	40.39	9.85

Source: S&P Global Market Intelligence. Standard template. Financial Sources.